StockData
Royalty Pharma plc logo

Royalty Pharma plc (RPRX) stock

RPRXNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 4, 2026Score 8/3049% above fair value
$68.53−0.78 (-1.13%)

Close on Nov 16, 2026Market cap $39.40BP/E 38.9Yield –

Royalty Pharma total debt

Total debt is short-term plus long-term borrowings on the balance sheet at the end of each period.

Royalty Pharma's total debt was $8.96B at Jun 30, 2026. For fiscal 2025 it was $8.95B, up 17.6% from the year before. The highest annual figure on record is $8.95B in fiscal 2025.

Annual total debt

PeriodPeriod endValueChange
FY2025Dec 31, 2025$8.95B+17.6%
FY2024Dec 31, 2024$7.61B+24.1%
FY2023Dec 31, 2023$6.14B-13.8%
FY2022Dec 31, 2022$7.12B+0.3%
FY2021Dec 31, 2021$7.10B+22.0%
FY2020Dec 31, 2020$5.82B-6.8%
FY2019Dec 31, 2019$6.24B–

Quarterly total debt

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026$8.96B+12.0%
Q1 FY2026Mar 31, 2026$8.96B+17.6%
Q4 FY2025Dec 31, 2025$8.95B+17.6%
Q3 FY2025Sep 30, 2025$8.95B+17.6%
Q2 FY2025Jun 30, 2025$8.00B+5.3%
Q1 FY2025Mar 31, 2025$7.62B+24.1%
Q4 FY2024Dec 31, 2024$7.61B+24.1%
Q3 FY2024Sep 30, 2024$7.61B+24.1%
Q2 FY2024Jun 30, 2024$7.60B+6.7%
Q1 FY2024Mar 31, 2024$6.14B-13.8%
Q4 FY2023Dec 31, 2023$6.14B-13.8%
Q3 FY2023Sep 30, 2023$6.13B-13.8%
Q2 FY2023Jun 30, 2023$7.13B+0.3%
Q1 FY2023Mar 31, 2023$7.12B+0.3%
Q4 FY2022Dec 31, 2022$7.12B+0.3%
Q3 FY2022Sep 30, 2022$7.11B+0.3%
Q2 FY2022Jun 30, 2022$7.11B+22.0%
Q1 FY2022Mar 31, 2022$7.10B+22.0%
Q4 FY2021Dec 31, 2021$7.10B+22.0%
Q3 FY2021Sep 30, 2021$7.09B+22.0%
Q2 FY2021Jun 30, 2021$5.83B-1.5%
Q1 FY2021Mar 31, 2021$5.82B-6.7%
Q4 FY2020Dec 31, 2020$5.82B–
Q3 FY2020Sep 30, 2020$5.81B–
Q2 FY2020Jun 30, 2020$5.91B–
Q4 FY2019Dec 31, 2019$6.24B–

More Royalty Pharma figures

See a number that looks wrong?